St. Jude Medical Inc. (NYSE:STJ) won pre-market approval for 2 next-generation cardiac ablation systems this month, the Therapy Cool Path Duo and Safire Blu Duo catheters.
Both ablation systems use radiofrequency energy to freeze small areas of faulty cardiac tissue in patients with typical trial flutter, a type of arrhythmia in which patients experience abnormal heart rhythms or an abnormally fast heartbeat in the upper chambers of the heart.
The Irvine, Calif.-based company also won approval for a new model cardiac ablation generator, according to FDA documents (PDF).
Both catheter systems have already been approved in Europe and in several Asia Pacific markets, St. Jude spokeswoman Amy Jo Meyer told MassDevice in an email.
Cook wins Canadian approval for Zenith endovascular graft
Following Health Canada approval, Cook Medical prepares to launch the Zenith Low Profile AAA endovascular graft to physicians north of the border. Read more
Hitachi and Horizon land Health Canada approval for CT system
Hitachi Medical Systems America and Horizon Medical Services are pleased to announce that they have received Health Canada approval for the Scenaria 64-slice CT System. Read more
SenoSense wins Canadian investigational approval for Densitrode
SenoSense Medical Systems Inc., a medical device company engaged in the development of innovative technologies targeted to reducing the impact of breast cancer in younger women, received an Investigational Testing Approval from Health Canada. Read more
Intuitive Surgical confirms Japanese reimbursement for prostatectomy
Intuitive Surgical (NSDQ:ISRG) confirmed that Japanese reimbursement for prostate surgeries using the da Vinci robot-assisted surgical system will begin in April. Read more
Medi-tate announces CE Mark for prostate device
Israel’s Medi-tate Ltd. won CE Mark approval in the European Union for its benign prostate hyperplasia device, used in procedures to reshape the urethra. Read more
ETView files 510(k) for endobronchial blocker
Israeli company ETView (TASE: ETVW) announced that the company has filed a 510(k) application with the FDA. The company expects feedback during the next quarter and anticipates entering the U.S. market with the Viva EB during 2012. Additional pre-market regulatory filings in Europe and Asia are anticipated during 2012. Read more
MindChild Medical files 510(k) for heart rate monitor
MindChild Medical Inc. completed filing its 510(k) application with the FDA for its Meridian non-invasive fetal heart monitor. MindChild expects feedback from the FDA during the next quarter and anticipates entering the U.S. market following clearance. Read more
Navidea’s Lymphoseek lands positive guidance from European Medicines Agency
Navidea Biopharmaceuticals Inc. (NYSE:NAVB) intends to file a Marketing Authorization Application in the EU for Lymphoseek based on clinical data accumulated from completed pivotal studies and supporting clinical literature. Read more